Key result
Recent management era linked to ~11% higher 3-year survival in not-operated CTEPH.
Why the study?
Treatment options for inoperable CTEPH have evolved with the availability of balloon pulmonary angioplasty and pulmonary vasodilators, prompting analysis of prognostic variables associated with long-term outcome.
Does the recent management era, including the availability of balloon pulmonary angioplasty, improve survival in patients with not-operated chronic thromboembolic pulmonary hypertension compared to the early management era?
Population
343 newly diagnosed consecutive patients with not-operated CTEPH
Comparison
Diagnosis in recent period (since 2013) vs early period (2006-2012)
Design
Cohort study
Authors
Loading...
Recent-era survival gains in inoperable CTEPH may support BPA consideration; observational data leaves causal effects open for randomized trials.
Cohort (n=343)
No
Does the recent management era, including the availability of balloon pulmonary angioplasty, improve survival in patients with not-operated chronic thromboembolic pulmonary hypertension compared to the early management era?
Absolute Event Rate: 85% vs 74.3%
p-value: p=0.030
Survival of patients with inoperable chronic thromboembolic pulmonary hypertension has significantly improved in the recent era, with balloon pulmonary angioplasty being an independent predictor of improved survival.
Taniguchi et al. (2019) conducted a cohort in not-operated chronic thromboembolic pulmonary hypertension (n=343). Recent diagnosis period (since 2013) vs. Early diagnosis period (2006-2012) was evaluated on 3-year survival (p=0.030). Diagnosis in the recent era (since 2013) was associated with improved 3-year survival compared to the early era (85.0% vs 74.3%, p=0.030) in patients with not-operated CTEPH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: